Kite Pharma (KITE): Zuma-1 Debate Not Significant - Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Juno Situation Has Little Impact on Kite Pharma's (KITE) Ongoing ZUMA1 Pivotal Trial - Stifel
November 23, 2016 10:33 AM ESTStifel analyst Thomas Shrader weighed in on Kite Pharma (NASDAQ: KITE) after rival Juno Therapeutics has again placed the ROCKET trial on clinical hold following patient deaths due to cerebral edema. The firm reiterated a Buy rating and price target of $74 on KITE, saying this reinforces Kite's R&D focus. They believe this situation has little impact on the ongoing ZUMA1 pivotal... More
